SINGAPORE, Nov. 20, 2025 /PRNewswire/ — JOYY Inc. (NASDAQ: JOYY) (“JOYY” or the “Company”), a global leading technology company, announced its unaudited financial results for the third quarter of 2025.

In the third quarter of 2025, JOYY’s revenue reached US$540 million, representing 6.4% quarter-over-quarter growth. Its livestreaming revenue was US$388 million, up 3.5% quarter-over-quarter, marking two consecutive quarters of sequential growth. Meanwhile, BIGO Ads recorded US$104 million in revenue, with a year-over-year growth of 33.1%, bringing total non-livestreaming revenue, including ad revenue and others, to 28.1% of the Company’s revenue. JOYY’s GAAP and non-GAAP¹ operating income increased approximately 19.1% and 16.6% year-over-year to US$20 million and US$41 million, respectively. JOYY’s non-GAAP¹ EBITDA reached US$51 million, up 16.8% year-over-year and 4.9% quarter-over-quarter. Operating cash flow for the third quarter reached US$73 million. As of September 30, the company held US$3.32 billion in net cash, providing strong support for its ongoing shareholder returns.

JOYY remains committed to delivering sustainable returns to shareholders. The Company previously announced a shareholder return program of approximately US$900 million through dividends and share repurchases from 2025 through 2027. JOYY has distributed US$148 million in dividends and repurchased US$89 million worth of shares from January 1, 2025 through November 14, 2025.

Ms. Ting Li, Chairperson and Chief Executive Officer of JOYY, commented, “In the third quarter of 2025, we sustained a steady sequential recovery in our livestreaming revenue while accelerating top-line growth in our advertising business. We made significant progress in advancing our dual growth engine strategy and strengthening synergies within our ecosystem. BIGO Ads achieved revenue growth both year-over-year and quarter-over-quarter. As we approach 2026, we are positioned for a resumption in year-over-year group-level revenue growth, with our livestreaming business expected to return to a steady positive trajectory and our advertising technology and smart commerce SaaS businesses poised to deliver robust revenue growth. We are leveraging the powerful synergies of our integrated ecosystem to strengthen our position as a global technology company, and we remain dedicated to generating sustained long-term value for our shareholders.”

Third Quarter 2025 Financial Highlights

• Net revenues in the third quarter of 2025 were US$540 million, representing an increase of 6.4% from US$508 million in the second quarter of 2025.

– Livestreaming revenue was US$388 million, representing an increase of 3.5% from US$375 million in the second quarter of 2025.

– Advertising revenue increased by 29.2% to US$113 million from US$87 million in the corresponding period of 2024 and by 17.1% from US$96 million in the second quarter of 2025.

– Other revenues increased by 22.3% to US$39 million from US$32 million in the corresponding period of 2024 and by 8.3% from US$36 million in the second quarter of 2025.

• Operating income was US$20 million in the third quarter of 2025, representing an increase of 19.1% from US$16 million in the corresponding period of 2024.
• Non-GAAP¹ EBITDA was US$51 million in the third quarter of 2025, representing an increase of 16.8% from US$43 million in the corresponding period of 2024.  
• Net income from continuing operations attributable to controlling interest of JOYY was US$62 million in the third quarter of 2025, representing an increase of 2.3% from US$61 million in the corresponding period of 2024.
• Non-GAAP¹ net income from continuing operations attributable to controlling interest and common shareholders of JOYY was US$72 million in the third quarter of 2025, compared to US$61 million in the corresponding period of 2024, representing a 18.4% year-over-year increase.
• Net Cash as of September 30, 2025 was US$3.32 billion.
• Net cash from operating activities was US$73 million, compared with US$61.1 million in the corresponding period of 2024.

Third Quarter 2025 Business Highlights

Livestreaming Business

In the third quarter, JOYY’s global average mobile MAUs reached 266 million, up 1.4% quarter-over-quarter. The acquisition of high-quality global users traffic effectively supports livestreaming monetization. In the third quarter, the Company’s livestreaming revenue reached US$388 million. BIGO livestreaming revenue was US$368 million, up 3.5% quarter-over-quarter, maintaining the sequential growth trend. BIGO’s total paying users grew 0.8% quarter-over-quarter, while ARPPU increased 3.4% quarter-over-quarter.

Bigo Live delivered positive sequential growth for the second consecutive quarter. This recovery reflects its comprehensive, integrated approach, where the business has leveraged effective streamer incentive programs, a healthy and diverse high-quality content ecosystem, AI-powered user touchpoint enhancements which improve content discovery and payment experiences, and strong local operational campaigns.

Since the second half of last year, Bigo Live has restructured its streamer incentive mechanisms across regions, improving streamer engagement and content quality across the platform. In the third quarter, average streaming hours for newly signed streamers on Bigo Live rose 3.5% quarter-over-quarter and average viewer numbers increased 3.9% quarter-over-quarter.

Bigo Live continues advancing AI-powered improvements across content distribution and payment experiences. By incorporating richer user signals through AI and optimizing strategies for cross-regional and in-app scenarios in Bigo Live, it enhanced viewing experiences and drove users’ average viewing time up 3.4% quarter-over-quarter. Meanwhile, the real-time translation subtitles now support 15 languages, significantly improving user interactions across different regions. Bigo Live is also using AIGC technology to efficiently generate localized virtual gifts. In October, AI-powered interactive gifts represented 25% of total virtual gift consumption, demonstrating strong user adoption of AI-enhanced features. Bigo Live also used targeted strategies to further optimize its tiered paying user benefits system. In the third quarter, mid-tier user ARPPU increased 2% quarter-over-quarter, while the total number of premium paying users achieved double-digit quarter-over-quarter growth.

Advertising Business

While livestreaming revenue has continued to grow steadily quarter over quarter this year, JOYY’s ad-tech platform, BIGO Ads, has delivered accelerated top-line growth. In the third quarter, BIGO Ads achieved US$104 million in advertising revenue, up 33.1% year-over-year and 19.7% quarter over quarter. BIGO Audience Network revenue was particularly strong, recording mid-double-digit year-over-year growth and 25% sequential growth.

BIGO Ads has continued to expand its third-party traffic by deepening integrations with mediation platforms and mobile app developers. In the third quarter, SDK ad requests were up 228% year-over-year and 29% quarter-over-quarter.

During the quarter, BIGO Ads upgraded its IAA D7 ROAS optimization with AI-driven, real-time prediction and bidding capabilities. The enhancement enables advertisers to scale budgets with greater confidence, acquiring higher-quality users while maintaining strong return efficiency.

BIGO Ads delivered strong growth across the board, driven by algorithm iterations, increased traffic volume, new market expansion, and strong advertiser demand across multiple verticals. BIGO Ads’ daily gross revenue reached new heights, and continues to grow with strong momentum. Improved ad delivery and effectiveness substantially drove advertisers spending. Total spending from key cohorts increased by 30% quarter-over-quarter. At the same time, performance gains attracted a steady influx of new advertisers, with the number of key cohorts up by 17% quarter-over-quarter.

During the third quarter, BIGO Ads continued to deepen its penetration in developed countries, with revenue in North America growing 22% quarter-over-quarter and that in Western Europe rising 41%, laying a strong foundation for its continued growth.

1.This press release includes certain non-GAAP financial measures as additional clarifying items to aid investors in further understanding the Company’s performance and the impact that these items and events had on the financial results. The non-GAAP financial measures provided above should not be considered as a substitute for, or superior to, the measures of financial performance prepared in accordance with GAAP. For details of the non-GAAP measures, including the reconciliations of GAAP measures to non-GAAP measures, please refer to the press release titled “JOYY Reports Third Quarter 2025 Unaudited Financial Results” issued by the Company on November 20, 2025.

SYDNEY, Nov. 20, 2025 /PRNewswire/ — Leading global cryptocurrency exchange KuCoin has signed on as an Official Partner and exclusive crypto exchange partner of the 2025 BMW Australian PGA Championship at Royal Queensland Golf Club on November 27-30.

The partnership with one of Australian golf’s major events comes as KuCoin expands its presence in Australia. Earlier this week, the exchange unveiled its new Sydney CBD headquarters along with local leadership to advance compliance, operations, and innovation.

The collaboration will see KuCoin integrated into a range of tournament activities, with on-course branding, fan engagement experiences, and digital activations that highlight the company’s commitment to accessibility, trust, and technological excellence.

The announcement follows the recent appointment of Australian golf icon Adam Scott as KuCoin’s first-ever global brand ambassador.

“Partnering with the 2025 BMW Australian PGA Championship is a natural extension of KuCoin’s long-term commitment to Australia,” said BC Wong, CEO of KuCoin. “With Adam Scott representing KuCoin on the world stage and our new Sydney hub anchoring our local innovation efforts, we are deepening our investment in Australia’s digital future. This partnership goes beyond sport; it underscores our belief in integrity, security, and the enduring trust we aim to build with communities across the region.”

PGA of Australia CEO Gavin Kirkman welcomed the new partnership, saying: “We’re thrilled to welcome KuCoin to the PGA family as a partner of the 2025 BMW Australian PGA Championship. Their commitment to innovation aligns perfectly with the values of our sport. Having Adam Scott, one of Australia’s most respected athletes, represent both golf and KuCoin makes this collaboration even more meaningful.”

“I am very happy to see KuCoin supporting professional golf in Australia,” Adam Scott added. “This tournament means a lot to me and I’m proud to have KuCoin by my side.”

The 2025 BMW Australian PGA Championship will feature a field that is headlined by Adam Scott, Cam Smith, Min Woo Lee, Joaquin Niemann, Ryan Fox, Cam Davis, Marc Leishman, Marco Penge, Carlos Ortiz, Matt Jones, Sebastien Munoz and defending champion Elvis Smylie.

About KuCoin

Founded in 2017, KuCoin is a leading global crypto platform built on trust, serving over 40 million users across 200+ countries and regions. With established recognition for its reliability, the platform leverages cutting-edge blockchain technology, robust liquidity solutions, and advanced user account protections to deliver a secure trading environment. KuCoin offers access to 1,000+ digital assets and solutions, including Web3 wallet, Spot and Futures trading, institutional services, and payments. Recognised by Forbes as one of the “Best Crypto Apps & Exchanges” and a “Top 50 Global Unicorn” by Hurun. KuCoin holds SOC 2 Type II, ISO 27001:2022, ISO 27701:2025, and CCSS certifications and is committed to security, compliance, and innovation under the leadership of CEO BC Wong. Notably, KuCoin is the only top global exchange to have achieved all four major security certifications, underscoring its industry-leading standards in safeguarding user assets.

Learn more: https://www.kucoin.com/en-au

 ABOUT PGA OF AUSTRALIA 

 The PGA of Australia is a not-for-profit Member-based organisation representing both Tournament Professionals and the Club Professionals who form the cornerstone of the industry, working in golf facilities throughout Australia and overseas. PGA Members play an integral role in servicing more than 3.5 million Australians who play golf in all its forms each year. The PGA of Australia also owns and manages the Challenger PGA Tour of Australasia which is a member of the International Federation of PGA Tours. The BMW Australian PGA Championship, Australian Open and New Zealand Open presented by Sky Sports are just a few of our sanctioned tournaments that carry Official World Golf Ranking Points. To ensure the Australian golf industry maintains its position as one of the best in the world, the PGA of Australia provides industry specific training and education opportunities for those seeking to start, advance or consolidate their career in the golf industry.

SHANGHAI and HONG KONG, Nov. 20, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that at the R&D Day taking place today, it will present the latest data and future plans for three mid/late-stage clinical programs, including ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]), ATG-037 (oral CD73 small molecule inhibitor), and ATG-101 (PD-L1/4-1BB bispecific antibody). The company will also share the latest progress on ATG-125 (B7H3 x PD-L1 bispecific ADC): A B7H3 x PD-L1 targeted therapy featuring “IO + ADC” dual-effect molecules for the treatment of solid tumors and its AnTenGager™ T-cell engager (TCE) technology platform which incorporates steric hindrance masking, along with updates on several key preclinical programs. In addition, guest expert Prof. Xin Wang, Chief Physician, Drug Clinical Trial Center, National Cancer Center / Cancer Hospital of the Chinese Academy of Medical Sciences, will deliver a keynote session sharing her insights on ATG-022.

The event will be held today at 14:00 (Beijing Time), both in-person at the Antengene Shanghai office and online via webcast. For further information on how to join the event, please refer to: https://www.antengene.com/newsinfo/451

1. Building a pipeline of first/best-in-class innovative therapies with strategic focus on four areas

To address major unmet medical needs in the APAC region and globally amid the rapidly evolving innovative drug landscape, Antengene has adopted a forward-looking strategy to build a diverse portfolio covering four major areas – ADCs, immuno-oncology (IO), autoimmune diseases, and TCEs.

• ADCs: ATG-022 (CLDN18.2 ADC) is advancing smoothly through clinical development and has generated a steady stream of promising data. In addition, two “IO + ADC” dual-mechanism candidates targeting B7-H3 x PD-L1 and CD24 are progressing well in preclinical development.
• IO: ATG-037 (oral CD73 small molecule inhibitor) and ATG-101 (PD-L1/4-1BB bispecific antibody) are progressing smoothly through clinical studies.
• Autoimmune diseases: ATG-201 (CD19×CD3 TCE), which is advancing toward clinical studies for the treatment of autoimmune diseases, can mediate complete B cell depletion with reduced risk of cytokine release syndrome (CRS). ATG-207 (undisclosed bifunctional biologics), is a first-in-class preclinical program being developed for T-cell driven autoimmune diseases.
• TCEs: Antengene has built a robust portfolio of first/best-in-class programs targeting CD19×CD3, CDH6×CD3, ALPPL2×CD3, LY6G6D×CD3, GPRC5D×CD3, LILRB4×CD3, and FLT3×CD3, offering a wide therapeutic window for addressing unmet clinical needs across autoimmune diseases, solid tumors, and hematologic malignancies.

2. Encouraging data set a solid foundation for further advancement in clinical development

▶ ATG-022 (CLDN18.2 ADC)

• Latest data from the Phase I/II CLINCH study: As of November 10, 2025, in patients with moderate to high CLDN18.2 expression (IHC 2+ > 20%), the 2.4 mg/kg dose cohort achieved an objective response rate (ORR) of 40% (12/30), a disease control rate (DCR) of 90% (27/30), and a median overall survival (mOS) of 14.72 months; while the 1.8 mg/kg dose cohort achieved an ORR of 40% (12/30), a DCR of 86.7% (26/30), and a median progression-free survival (mPFS) of 5.45 months. Among patients with low/ultra-low CLDN18.2 expression (IHC 2+ ≤ 20%), those treated at the efficacious dose range of 1.8-2.4 mg/kg achieved an ORR of 28.6% (6/21) and a DCR of 52.4% (11/21). In these results, ATG-022 demonstrated potent antitumor activity in patients with a broad range of CLDN18.2 expression levels.
• Broad combinatory potential for front-line treatment: the 1.8 mg/kg cohort demonstrated promising efficacy with only 16.1% of patients experienced grade 3 or higher treatment-related adverse events (TRAEs). This differentiated safety profile uniquely positions ATG-022 as an ADC with best-in-class safety profile and potential to transform first-line standard of care in combination with both immune checkpoint inhibitors (CPIs) and chemotherapy.
• Three clinical development pathways: To fully realize the therapeutic potential of its CLDN18.2-targeted therapy ATG-022, Antengene has outlined a clear clinical development roadmap designed to achieve regulatory approval, maximize therapeutic reach, and broaden tumor-type coverage. The strategy includes a near-term approval path through a pivotal Phase III in third and later line gastric cancer patients with moderate to high CLDN18.2 expression; a front-line proof-of-concept Phase II study evaluating ATG-022 in combination with a CPI and the CAPOX regimen, which, if supported by positive results, is expected to advance into a Phase III trial; and A broad indication-expansion effort through the ongoing Phase II study that builds on encouraging activity signals, extending beyond gynecologic tumors to further assess ATG-022 across a wider range of solid tumor types.

▶ ATG-037 (oral CD73 small molecule inhibitor)

• Latest data from the Phase I/Ib STAMINA-01 study: As of October 24, 2025, in the subgroup of patients with CPI-resistant melanoma who received the combination regimen (12 patients), the ORR was 33.3%, the DCR was 100%, including 1 complete response (CR) and 3 partial responses (PRs). One of these patients had maintained CR and reported no safety issues despite having been on the treatment for more than two years. In the subgroup of patients with CPI-resistant non-small cell lung cancer (14 patients), the ORR was 21.4%, the DCR was 71.4%, including 3 PRs. These findings suggest that ATG-037 has clinically meaningful therapeutic potential in multiple tumor types, particularly in patients who are CPI-resistant.
• Clinical development pathways: existing data show that ATG-037 holds enormous therapeutic potential for the treatment of first-line or CPI-resistant melanoma, with promising potential for expansion into other tumor types. Antengene’s clinical development roadmap for ATG-037 has four main components: 1. combination with CPI for the treatment of CPI-resistant unresectable and metastatic melanoma (second-line treatment); 2. combination with CPI for the first-line treatment of unresectable or metastatic melanoma; 3. active expansion into other tumor types supported by the encouraging proof-of-concept data in CPI-resistant non-small cell lung cancer; 4. explore potential combinations with next-generation CPIs such as PD-1×VEGF bispecific antibody.

▶ ATG-101 (PD-L1/4-1BB bispecific antibody): dose-escalation study of ATG-101 is currently underway in China, the U.S., and Australia, and has already observed favorable safety in varies dosing regimens, thus laying a solid foundation for the future clinical development. One study evaluating ATG-101 in extrapulmonary neuroendocrine carcinoma (EP-NEC) patients will be initiated soon.

3. AnTenGager™ technology platform: a key driver of innovation

▶ A TCE platform featuring steric hindrance masking: AnTenGager™ is a proprietary “2+1” second-generation TCE technology platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize CRS and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune diseases, solid tumors and hematological malignancies indications. Leveraging this platform, Antengene has discovered multiple investigational programs:

• ATG-201 (CD19 x CD3 TCE): ATG-201 is a novel “2+1” CD19-targeted T-cell engager developed on the AnTenGager^TM TCE platform for the treatment of B cell related autoimmune diseases. Preclinical data presented at the 2025 American College of Rheumatology (ACR) Annual Meeting showed that in non-human primate (NHP) models, the monkey surrogate of ATG-201 achieved deep and durable depletion of naïve B cells with a favorable safety profile, characterized by only a very mild and transient increase in cytokine levels. The IND-enabling study of ATG-201 has been completed and the IND-submission is under preparation.
• ATG-106 (CDH6 x CD3 TCE): A global first-in-class CDH6 x CD3 targeted TCE being developed for the treatment of ovarian cancer and kidney cancer.
• ATG-110（LY6G6D x CD3 TCE): A potential global best-in-class LY6G6D x CD3 targeted TCE being developed for the treatment of microsatellite stable colorectal cancer.
• ATG-112 (ALPPL2 x CD3 TCE): A global first-in-class ALPPL2 x CD3 targeted TCE being developed for the treatment of gynecologic tumors and lung cancer.
• ATG-125 (B7H3 x PD-L1 bispecific ADC): A B7H3 x PD-L1 targeted therapy featuring “IO + ADC” dual-effect molecules for the treatment of solid tumors.
• ATG-207 (undisclosed bifunctional biologics): a global first-in-class bifunctional biologic agent being developed for the treatment of T-cell driven autoimmune diseases, a therapeutic area representing a huge unmet clinical need.

Antengene will strive to further accelerate these highly promising clinical and preclinical programs. The company plans to report additional progress of these innovative programs and update the medical community, patients, and investors on future developmental milestones at a series of upcoming top international conferences.

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com  

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com 

HONG KONG, Nov. 20, 2025 /PRNewswire/ — China Mobile International Limited (CMI), along with seven global partners including Bayobab, center3, Meta, Orange, Telecom Egypt, Vodafone Group, and WIOCC, has jointly completed the core 2Africa Submarine Cable Infrastructure (2Africa). Circling the African continent and connecting intercontinental nodes across Europe, Asia, and beyond, the 2Africa will further expand CMI’s global submarine cable layout and international connectivity resources, providing a robust digital infrastructure to accelerate the digital economic development in Africa and the surrounding regions.

As the first cable to continuously link Africa’s east and west within a single system, 2Africa adopts an open-access model. Spanning over 45,000 kilometers, it connects 33 + countries / regions across Africa, the Middle East, Europe, and Asia, with a design capacity of 180Tbps. According to estimates, 2Africa is projected to contribute up to USD36.9 billion to Africa’s GDP within the first two to three years of operation.

Following the commissioning of the 2Africa’s key segments, CMI has further optimized resource allocation along the Arabian Sea, the eastern and western coasts of Africa, and Europe. It has also created synergies with high-capacity submarine cables along the eastern and western coasts of Africa such as PEACE and Equiano, enabling CMI to enhance the multi-ring network covering Africa. Leveraging global network resources in Djibouti, Tanzania, Kenya, South Africa, Nigeria, and other locations, as well as submarine cable systems such as IAX-IEX, 2Africa integrates Eurasia-Africa’s high-capacity bandwidth with extensions of local terrestrial cable and PoP. This initiative aims to build a leading regional international submarine cable connectivity that covers Africa while extending its influence to Asia-Pacific and Europe.

CMI leverages 2Africa’s technical advantages of “high-bandwidth and low-latency” to form powerful synergies with the company’s existing cloud-network capabilities, including over 100 submarine and terrestrial cables, 380+PoPs, and 1,270+ data centers worldwide. This robust infrastructure allows CMI to provide global carrier customers with high-quality international private lines, cloud private lines, and interconnection services covering multiple core cities in Africa and extending to the African interior. Together with the mCloud cloud-network integration portal with a one-stop integrated package featuring “a unified platform, one country, one price, one-click ordering, and end-to-end services,” CMI offers AI+ cloud-network integration solutions for enterprises to step into Africa and the Middle East markets, as well as local partners. These solutions focus on key African industries, such as AI+ Smart Energy Mining and AI+ Smart Park, driving the region toward an AI-powered digital intelligence future.

CMI has been tapping into the African market since 2015. The completion of the core 2Africa submarine cable infrastructure will further enrich network resources in the African region, delivering high-quality, reliable connectivity to critical sectors such as education, healthcare, and financial services, thereby accelerating Africa’s digital transformation and improving the lives of communities across the continent.

Looking ahead, CMI will continue to leverage submarine cable projects such as the 2Africa to accelerate the implementation of new information infrastructure and new information service system in Africa, contributing digital and intelligent solutions to the continent and comprehensively supporting the vigorous development of Africa’s digital economy.